Biblio

Export 71 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809PDF icon Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
Veikkola T, Lohela M, Ikenberg K, Mäkinen T, Korff T, Saaristo A, et al.. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J [Internet]. 2003;17(14):2006 - 13. http://view.ncbi.nlm.nih.gov/pubmed/14597670PDF icon Tanja Veikkola et al., FASEB Journal 2006 (598.77 KB)
Mukenge S, Jha SK, Catena M, Manara E, Leppänen V‐M, Lenti E, et al.. Investigation on the role of biallelic variants in VEGF‐C found in a patient affected by Milroy‐like lymphedema. Molecular Genetics & Genomic Medicine [Internet]. 2020;00:e1389. https://onlinelibrary.wiley.com/doi/abs/10.1002/mgg3.1389PDF icon Mukenge et al. 2020 (1.06 MB)
Dashkevich A, Raissadati A, Syrjälä SO, Zarkada G, Keränen MAI, Tuuminen R, et al.. Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. American Journal of Transplantation [Internet]. 2015;16(4):1160-1172. http://onlinelibrary.wiley.com/doi/10.1111/ajt.13564/abstract
L
Jeltsch M. Lymphangiogenesis in Health and Disease [Internet]. 41st European Societry of Lymphology (ESL) Congress. Lausanne, Switzerland: European Group of Lymphology; 2015. http://www.eurolymphology.org/JOURNAL/VOL26-N72-2015/#p=10PDF icon Abstract of the Presentation (Michael Jeltsch) (75.34 KB)
Krebs R, Jeltsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Basic principles and embryonic development. [bilingual: English, German]. Lymphologie in Forschung und Praxis [Internet]. 2013;17(1):30 - 37. http://jeltsch.org/sites/jeltsch.org/files/JeltschMichael_Lymphforsch2013_30.pdfPDF icon Krebs & Jeltsch (2013): The lymphangiogenic growth factors VEGF-C and VEGF-D. Part 1: Fundamentals and embryonic development. (2.08 MB)PDF icon Krebs & Jeltsch (2013): Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 1. Grundlagen und Embryonalentwicklung. (1.82 MB)
Schaupper MV, Jeltsch M, Rohringer S, Redl H, Holnthoner W. Lymphatic Vessels in Regenerative Medicine and Tissue Engineering. Tissue Engineering Part B [Internet]. 2016;22(5):1-13. http://online.liebertpub.com/doi/10.1089/ten.TEB.2016.0034PDF icon Schaupper et al. Tissue Engineering Part B. Review (postprint manuscript = accepted version after peer review). (697.3 KB)
Gucciardo E, Lehti TA, Korhonen A, Salvén P, Lehti K, Jeltsch M, et al.. Lymphatics and the eye. [Finnish]. Duodecim Lääketieteellinen Aikakauskirja [Internet]. 2020;136(16):1777-1788. https://www.duodecimlehti.fi/lehti/2020/16/duo15739PDF icon Gucciardo et al. Lymphatics and the Eye (English version). (3.31 MB)
S
Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, et al.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889PDF icon Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, et al.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. In Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001. PDF icon Jussila et al., 2001 (279.47 KB)
Leppänen V-M, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, et al.. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(32):12960 - 12965. http://www.pnas.org/content/110/32/12960.long
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116PDF icon Veli-Matti Leppänen et al. PNAS 2010 (1 MB)PDF icon Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, et al.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085PDF icon Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB)PDF icon Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstractPDF icon J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)

Pages